306 related articles for article (PubMed ID: 33176185)
1. Targeted delivery of small noncoding RNA for glioblastoma.
Yoo JY; Yeh M; Kaur B; Lee TJ
Cancer Lett; 2021 Mar; 500():274-280. PubMed ID: 33176185
[TBL] [Abstract][Full Text] [Related]
2. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model.
Lee TJ; Haque F; Shu D; Yoo JY; Li H; Yokel RA; Horbinski C; Kim TH; Kim SH; Kwon CH; Nakano I; Kaur B; Guo P; Croce CM
Oncotarget; 2015 Jun; 6(17):14766-76. PubMed ID: 25885522
[TBL] [Abstract][Full Text] [Related]
3. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21.
Lee TJ; Yoo JY; Shu D; Li H; Zhang J; Yu JG; Jaime-Ramirez AC; Acunzo M; Romano G; Cui R; Sun HL; Luo Z; Old M; Kaur B; Guo P; Croce CM
Mol Ther; 2017 Jul; 25(7):1544-1555. PubMed ID: 28109960
[TBL] [Abstract][Full Text] [Related]
4. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
5. Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.
Grafals-Ruiz N; Rios-Vicil CI; Lozada-Delgado EL; Quiñones-Díaz BI; Noriega-Rivera RA; Martínez-Zayas G; Santana-Rivera Y; Santiago-Sánchez GS; Valiyeva F; Vivas-Mejía PE
Int J Nanomedicine; 2020; 15():2809-2828. PubMed ID: 32368056
[TBL] [Abstract][Full Text] [Related]
6. Peptides used in the delivery of small noncoding RNA.
Shukla RS; Qin B; Cheng K
Mol Pharm; 2014 Oct; 11(10):3395-408. PubMed ID: 25157701
[TBL] [Abstract][Full Text] [Related]
7. MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.
Costa PM; Cardoso AL; Custódia C; Cunha P; Pereira de Almeida L; Pedroso de Lima MC
J Control Release; 2015 Jun; 207():31-9. PubMed ID: 25861727
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potentials of Noncoding RNAs: Targeted Delivery of ncRNAs in Cancer Cells.
Liu Y; Wang J
Adv Exp Med Biol; 2016; 927():429-58. PubMed ID: 27376745
[TBL] [Abstract][Full Text] [Related]
9. Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.
Xu C; Haque F; Jasinski DL; Binzel DW; Shu D; Guo P
Cancer Lett; 2018 Feb; 414():57-70. PubMed ID: 28987384
[TBL] [Abstract][Full Text] [Related]
10. Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
Van Woensel M; Wauthoz N; Rosière R; Mathieu V; Kiss R; Lefranc F; Steelant B; Dilissen E; Van Gool SW; Mathivet T; Gerhardt H; Amighi K; De Vleeschouwer S
J Control Release; 2016 Apr; 227():71-81. PubMed ID: 26902800
[TBL] [Abstract][Full Text] [Related]
11. Bioengineered Bacteriophage-Like Nanoparticles as RNAi Therapeutics to Enhance Radiotherapy against Glioblastomas.
Pang HH; Huang CY; Chen PY; Li NS; Hsu YP; Wu JK; Fan HF; Wei KC; Yang HW
ACS Nano; 2023 Jun; 17(11):10407-10422. PubMed ID: 37120837
[TBL] [Abstract][Full Text] [Related]
12. RNA Micelles for the Systemic Delivery of Anti-miRNA for Cancer Targeting and Inhibition without Ligand.
Yin H; Wang H; Li Z; Shu D; Guo P
ACS Nano; 2019 Jan; 13(1):706-717. PubMed ID: 30543397
[TBL] [Abstract][Full Text] [Related]
13. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.
Gandhi NS; Tekade RK; Chougule MB
J Control Release; 2014 Nov; 194():238-56. PubMed ID: 25204288
[TBL] [Abstract][Full Text] [Related]
14. RNAi-based therapeutics and tumor targeted delivery in cancer.
Kara G; Calin GA; Ozpolat B
Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells.
Li L; Liu J; Diao Z; Shu D; Guo P; Shen G
Mol Biosyst; 2009 Nov; 5(11):1361-8. PubMed ID: 19823753
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in Glioblastoma.
Tommasini-Ghelfi S; Lee A; Mirkin CA; Stegh AH
Methods Mol Biol; 2019; 1974():371-391. PubMed ID: 31099015
[TBL] [Abstract][Full Text] [Related]
17. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
18. Small RNA combination therapy for lung cancer.
Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
[TBL] [Abstract][Full Text] [Related]
19. Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles.
Cohen ZR; Ramishetti S; Peshes-Yaloz N; Goldsmith M; Wohl A; Zibly Z; Peer D
ACS Nano; 2015 Feb; 9(2):1581-91. PubMed ID: 25558928
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma.
Kievit FM; Wang K; Ozawa T; Tarudji AW; Silber JR; Holland EC; Ellenbogen RG; Zhang M
Nanomedicine; 2017 Oct; 13(7):2131-2139. PubMed ID: 28614736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]